PT  - JOURNAL ARTICLE
AU  - Muttamba, Winters
AU  - Lusiba, John
AU  - Namakula, Loryndah Olive
AU  - Byakika-Kibwika, Pauline
AU  - Ssali, Francis
AU  - Ddungu, Henry
AU  - Mugenyi, Levicatus
AU  - Kiwanuka, Noah
AU  - Sekibira, Rogers
AU  - Kityo, Cissy
AU  - Keyune, Dorothy
AU  - Acana, Susan
AU  - Musinguzi, Ambrose
AU  - Masasi, Ayub
AU  - Byamugisha, Joseph
AU  - Mpanju, David
AU  - Musoki, Walter Jack
AU  - Tukamuhebwa, Hellen Aanyu
AU  - Nakwagala, Fred
AU  - Bagaya, Bernard Sentalo
AU  - Kayongo, Alex
AU  - Kimuli, Ivan
AU  - Nantanda, Rebecca
AU  - Katagira, Winceslaus
AU  - Buregyeya, Esther
AU  - Byanyima, Rosemary
AU  - Byarugaba, Baterana
AU  - Siddharthan, Trishul
AU  - Mwebesa, Henry
AU  - Charles, Olaro
AU  - Joloba, Moses Lutaakome
AU  - Bazeyo, William
AU  - Kirenga, Bruce
TI  - Feasibility of collecting and processing of COVID-19 convalescent plasma for treatment of COVID-19 in Uganda
AID  - 10.1101/2020.10.29.20222067
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.10.29.20222067
4099  - http://medrxiv.org/content/early/2020/11/03/2020.10.29.20222067.short
4100  - http://medrxiv.org/content/early/2020/11/03/2020.10.29.20222067.full
AB  - Introduction Evidence that supports the use of COVID-19 convalescent plasma (CCP) for treatment of COVID-19 is increasingly emerging. However, very few African countries have undertaken the collection and processing of CCP. The aim of this study was to assess the feasibility of collecting and processing of CCP, in preparation for a randomized clinical trial of CCP for treatment of COVID-19 in Uganda.Methods In a cross-sectional study, persons with documented evidence of recovery from COVID-19 in Uganda were contacted and screened for blood donation via telephone calls. Those found eligible were asked to come to the blood donation centre for further screening and consent. Whole blood collection was undertaken from which plasma was processed. Plasma was tested for transfusion transmissible infections (TTIs) and anti-SARS CoV-2 antibody titers. SARS-CoV-2 testing was also done on nasopharyngeal swabs from the donors.Results 192 participants were contacted of whom 179 (93.2%) were eligible to donate. Of the 179 eligible, 23 (12.8%) were not willing to donate and reasons given included: having no time 7(30.4%), fear of being retained at the COVID-19 treatment center 10 (43.5%), fear of stigma in the community 1 (4.3%), phobia for donating blood 1 (4.3%), religious issues 1 (4.4%), lack of interest 2 (8.7%) and transport challenges 1 (4.3%). The median age was 30 years and females accounted for 3.7% of the donors. A total of 30 (18.5%) donors tested positive for different TTIs. Antibody titer testing demonstrated titers of more than 1:320 for all the 72 samples tested. Age greater than 46 years and female gender were associated with higher titers though not statistically significant.Conclusion CCP collection and processing is possible in Uganda. However, concerns about stigma and lack of time, interest or transport need to be addressed in order to maximize donations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding for this work was provided by the Government of Uganda through the Makerere University Research and Innovations Fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained from the Mulago Hospital Research and Ethics Committee (MHREC 1872), as well as the Uganda National Council for Science and Technology (HS684ES)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDataset analyzed during this study can be made available to all interested researchers upon reasonable request directed to the corresponding author